Citi resumes Ligand Pharma coverage with Buy rating, $387 target
Tweet Send to a Friend
(Updated - July 21, 2026 5:03 AM EDT)
Citi analyst Yigal Nochomovitz resumed coverage of Ligand Pharma (NASDAQ: LGND) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citi analyst Yigal Nochomovitz resumed coverage of Ligand Pharma (NASDAQ: LGND) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
